Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy
NCT03796962Phase 2Active, not recruiting
- Sponsor
- Xenon Pharmaceuticals
- Start
- Jan 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of azetukalner in focal epilepsy (4 arms), sponsored by Xenon Pharmaceuticals. Primary endpoint: Median Percent Change in Focal Seizure Frequency. Started Jan 2019; status: active, not recruiting.
02
Drugs
azetukalner
03
Conditions
focal epilepsy
Beyond the preview
Go deeper on NCT03796962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03796962.